Comparative Pharmacology
Head-to-head clinical analysis: DICLOFENAC SODIUM versus DIFLUNISAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DICLOFENAC SODIUM versus DIFLUNISAL.
DICLOFENAC SODIUM vs DIFLUNISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective COX-1 and COX-2 inhibitor, reducing prostaglandin synthesis via inhibition of cyclooxygenase, leading to anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Oral: 50 mg two to three times daily; maximum 150 mg/day. Topical: 1% gel applied four times daily. Rectal: 100 mg suppository once daily.
500 mg to 1000 mg orally initially, then 250 mg to 500 mg every 8 to 12 hours. Maximum daily dose: 1500 mg.
None Documented
None Documented
Clinical Note
moderateDiflunisal + Gatifloxacin
"Diflunisal may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateDiflunisal + Rosoxacin
"Diflunisal may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateDiflunisal + Levofloxacin
"Diflunisal may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateDiflunisal + Trovafloxacin
"Diflunisal may increase the neuroexcitatory activities of Trovafloxacin."
Terminal elimination half-life approximately 2 hours (range 1.3–3.1 h). Short half-life requires frequent dosing; no accumulation with normal dosing intervals.
8-12 hours (prolonged in renal impairment; clinical context: permits twice-daily dosing)
Approximately 65% renal as glucuronide conjugates and inactive metabolites, ~20% biliary/fecal. Less than 1% unchanged in urine.
Renal (90% as glucuronide conjugates, <5% unchanged); biliary/fecal (<10%)
Category D/X
Category C
NSAID
NSAID